loader
Please Wait
Applying Filters...

Annual Sales of Deutetrabenazine reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Menu
$ API Ref.Price (USD/KG) : 35,341Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 6Austedo

PharmaCompass

01

Brand Name : Austedo

Deutetrabenazine

arrow
Discovery on Target
Not Confirmed

Brand Name : Austedo

arrow
Discovery on Target
Not Confirmed

Deutetrabenazine

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2019 Revenue in Millions : 412

2018 Revenue in Millions : 204

Growth (%) : 102

blank

02

Brand Name : Austedo

Deutetrabenazine

arrow
Discovery on Target
Not Confirmed

Brand Name : Austedo

arrow
Discovery on Target
Not Confirmed

Deutetrabenazine

Main Therapeutic Indication : CNS & Anesthesia

Currency : USD

2020 Revenue in Millions : 637

2019 Revenue in Millions : 412

Growth (%) : 55

blank

03

Brand Name : Austedo

Deutetrabenazine

arrow
Discovery on Target
Not Confirmed

Brand Name : Austedo

arrow
Discovery on Target
Not Confirmed

Deutetrabenazine

Main Therapeutic Indication : Neurology

Currency : USD

2021 Revenue in Millions : 802

2020 Revenue in Millions : 637

Growth (%) : 26

blank

04

Brand Name : Austedo

Deutetrabenazine

arrow
Discovery on Target
Not Confirmed

Brand Name : Austedo

arrow
Discovery on Target
Not Confirmed

Deutetrabenazine

Main Therapeutic Indication : Neurology

Currency : USD

2022 Revenue in Millions : 963

2021 Revenue in Millions : 802

Growth (%) : 20

blank

05

Brand Name : Austedo

Deutetrabenazine

arrow
Discovery on Target
Not Confirmed

Brand Name : Austedo

arrow
Discovery on Target
Not Confirmed

Deutetrabenazine

Main Therapeutic Indication : Neurology

Currency : USD

2023 Revenue in Millions : 1,225

2022 Revenue in Millions : 963

Growth (%) : 27

blank

06

Brand Name : Austedo

Deutetrabenazine

arrow
Discovery on Target
Not Confirmed

Brand Name : Austedo

arrow
Discovery on Target
Not Confirmed

Deutetrabenazine

Main Therapeutic Indication : Neurological/Mental Disorders

Currency : USD

2018 Revenue in Millions : 204

2017 Revenue in Millions : 24

Growth (%) : 750%

blank